Bold-100 trial
WebOct 9, 2024 · BOLD-100 is a first-in-class ruthenium-based therapeutic that selectively inhibits stress-induced upregulation of GRP78 and alters the unfolded protein response (UPR), mitigating resistance,... WebJul 23, 2024 · BOLD-100 is a small molecule, which is transported into the tumour cell via the protein albumin and selectively activated there, resulting in the death of the cancer cells. Bold Therapeutics continues to actively enroll patients in its Phase 1b trial of BOLD-100 in combination with FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) for the ...
Bold-100 trial
Did you know?
WebMay 11, 2024 · "Importantly, we continue to gather additional data on BOLD-100 from our ongoing Phase 1b trial in the treatment of advanced gastric, pancreatic, colorectal and bile duct cancers and anticipate applying for one or more Breakthrough Therapy Designations for BOLD-100 as clinical efficacy data becomes available. Breakthrough Therapy … WebMar 1, 2024 · The Phase 2 (dose-expansion) portion of the seamless adaptive trial of BOLD-100 will enroll 80 additional patients at 13 investigational sites worldwide: 6 sites in Canada; 2 sites in the U.S ...
WebBOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of … WebJun 24, 2024 · While only the earliest efficacy data from the Phase 1b portion of the study was available for presentation at ASCO, the colorectal arm of the BOLD-100-001 Phase 2 trial has since fully enrolled (N=22) and Bold Therapeutics expects to announce additional efficacy data in mCRC by year-end.
Web1 day ago · Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 … WebBOLD-100, or sodium trans-[tetrachlorobis (1H-indazole)ruthenate(III)], is a ruthenium-based anti-cancer therapeutic in clinical development. As of November 2024, BOLD-100 …
WebMar 1, 2024 · BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and …
WebBOLD-100 is a ruthenium-based anticancer agent. BOLD-100 also is an inhibitor of stress-induced GRP78 upregulation, disrupting endoplasmic reticulum (ER) homeostasis and inducing ER stress and unfolded protein response (UPR). BOLD-100 interferes with the complex interplay between ER-stress response, lysosome dynamics, and autophagy … townsville to carmilaWebMar 1, 2024 · BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic that (1) alters the unfolded protein response (UPR) through selective GRP78 inhibition; and … townsville to cairns stopsWebJun 9, 2024 · BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease … townsville to ayrWebJan 20, 2024 · BOLD-100 successfully completed a Phase 1 monotherapy trial, with a manageable safety profile; it has demonstrated synergy in established preclinical models in combination with a wide variety of ... townsville to byron bayWebJul 19, 2024 · The ruthenium-based anticancer agent BOLD-100 just received an Orphan Drug Designation in the treatment of gastric (stomach) cancer from the U.S. Food and Drug Administration. The small molecule therapeutic originally developed as KP1019 (KP1339) by chemist and physician Bernhard Keppler from the University of Vienna, showed … townsville to brisbane mapWebBold Therapeutics is a clinical-stage biopharmaceutical company that was founded in 2024 by a team of industry veterans to develop and commercialize novel therapeutics. The company’s lead asset is BOLD … townsville to cairns busWebJan 22, 2024 · BOLD-100 successfully completed a Phase 1 monotherapy trial, with a manageable safety profile; it has demonstrated synergy in established preclinical models … townsville to cairns drive